AKAli Khalouei

Ali Khalouei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ali Khalouei has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Abdollah Jafarzaheh

    Department of Immunology, Medical School, Kerman University of Medical Sciences, Kerman, Iran

    1 shared publication
  • Arezu Khosravi Mashizi

    Department of Immunology, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran

    1 shared publication
  • Behjat Kalantari Khandani

    Department of Hematology and Oncology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran

    1 shared publication
  • Beydolah Shahouzehi

    Cardiovascular Research Center, Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran

    1 shared publication
  • Farnaz Sedghy

    Department of Immunology, Medical School, Kerman University of Medical Sciences, Kerman, Iran

    1 shared publication
  • Mohammad Mehdi Yaghoobi

    Research Department of Biotechnology, Institute of Science and High Technology and Environmental Sciences, Graduate University of Advanced Technology, Kerman, Iran

    1 shared publication

Latest Publications

  • Open Access

    Association of ERCC1 Gene Polymorphisms (rs3212986 and rs11615) With the Risk of Lung Cancer in a Population From Southeast Iran

    by Ali Khalouei, Yaser Masoumi-Ardakani, Abdollah Jafarzaheh, Behjat Kalantari Khandani, Farnaz Sedghy, Arezu Khosravi Mashizi, Mohammad Mehdi Yaghoobi, Mohammadreza Zangouey, Beydolah Shahouzehi

    Background: Polymorphisms within the excision repair cross-complementation group 1 (ERCC1), an essential component of DNA repair mechanisms, have been associated with various malignancies. This study aimed to evaluate the association of the single-nucleotide polymorphisms (SNPs) rs3212986 and rs11615 within the ERCC1 gene in non-small cell lung cancer (NSCLC) patients. Study Design: A case-control study. Methods: Genomic DNA was extracted from the peripheral blood samples of 83 NSCLC patients and 119 healthy individuals. The genetic diversity of SNPs rs3212986 and rs11615 was determined using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The RFLP results were confirmed through sequencing. Results: The TT genotype of the rs11615 SNP was associated with a higher risk of NSCLC development (odds ratio: 3.900, 95% confidence interval: 0.603, 22.866, P=0.050). Furthermore, the AA genotype of rs3212986 was related to a higher risk of NSCLC development (OR: 2.531, 95% CI: 1.017, 6.300, P=0.046). A significant association was observed between smoking and lung cancer (OR: 3.072, 95% CI: 1.715, 5.503, P<0.001). Moreover, among non-smokers, there was an association between lung cancer risk and the AA (OR: 6.825, 95% CI: 1.722, 27.044, P=0.006) and AC (OR: 2.503, 95% CI: 0.977, 6.412, P=0.056) genotypes of rs3212986. However, no correlation was found between the genotypes of these SNPs and patients’ sensitivity to cisplatin and carboplatin (P ˃ 0.05). Conclusion: The rs11615-related TT genotype and the rs3212986-related AA genotype may be associated with a higher risk of lung cancer development.